Results 41 to 50 of about 1,917,601 (292)

Airway remodelling rather than cellular infiltration characterises both type2 cytokine biomarker-high and -low severe asthma [PDF]

, 2022
Background: The most recognizable phenotype of severe asthma comprises people who are blood eosinophil and FeNO-high, driven by type-2 (T2) cytokine biology which responds to targeted biological therapies.
Timothy SC Hinks (8946323), Steve Bicknell, Peter Bradding, David F. Choy, UK Medical Research Council Refractory Asthma Stratification programme (RASP-UK) (12645328), Howarth, Peter H., Beverley Hargadon (7165109), Beverley Hargadon, Peter H. Howarth, Adel H Mansur (8950460), Mansur, Adel H., Symon, Fiona A, Fiona A Symon (12645319), Mansur, Adel H, Timothy S. C. Hinks, Vanessa Brown, McGarvey, Lorcan P., Peter H Howarth (8946326), Steve Bicknell (12645322), Hinks, Timothy S. C., Latifa Khalfaoui (11789273), Simon Couillard, Liam G. Heaney, Rekha Chaudhuri, Choy, David F., Choy, David F, Austin, Cary D., Fowler, Stephen J, Lorcan P McGarvey (11248995), Austin, Cary D, Symon, Fiona A., Stephen J. Fowler, Heaney, Liam G, Hinks, Timothy S C, Chaudhuri, Rekha, Latifa Khalfaoui, Pavord, Ian D., Arron, Joseph R, Shrimanker, Rahul, Couillard, Simon, Rahul Shrimanker, Vanessa Brown (12645325), McGarvey, Lorcan P, Lorcan P. McGarvey, Hargadon, Beverley, Fiona A. Symon, Ian D. Pavord, Stephen J Fowler (9382727), Joseph R Arron (8946332), Heaney, Liam G., Brown, Vanessa, David F Choy (8946329), Bradding, Peter, Fowler, Stephen J., Cary D Austin (9382673), Simon Couillard (8548080), Cary D. Austin, Rekha Chaudhuri (443727), Ian D Pavord (9382745), Howarth, Peter H, Rahul Shrimanker (7780091), Peter Bradding (60398), Adel H. Mansur, Joseph R. Arron, Arron, Joseph R., Pavord, Ian D, Liam G Heaney (8950457), Khalfaoui, Latifa, Bicknell, Steve   +68 more
core   +1 more source

Sputum Hyaluronan and Versican in Severe Eosinophilic Asthma [PDF]

International Archives of Allergy and Immunology, 2012
<b><i>Background:</i></b> We examined levels of hyaluronan, a matrix glycosaminoglycan and versican, a matrix proteoglycan, in the sputum of asthmatics treated with mepolizumab (anti-IL-5 monoclonal antibody) versus placebo to evaluate the utility of these measurements as possible biomarkers of asthma control and airway ...
Andrew G, Ayars, Leonard C, Altman, Sue, Potter-Perigo, Katherine, Radford, Thomas N, Wight, Parameswaran, Nair   +5 more
openaire   +2 more sources

Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy

Journal of Asthma and Allergy, 2021
Silvia Tognella,1 Claudio Micheletto,2 Alessandro Roggeri,3 Guido Polese,4 Denise Artioli,1 Gianenrico Senna,5 Marco Caminati,5,6 Daniela Paola Roggeri3 1Pulmonology Unit, Mater Salutis Hospital, Legnago (Verona), Italy; 2Pulmonology Unit, Azienda ...
Tognella S, Micheletto C, Roggeri A, Polese G, Artioli D, Senna G, Caminati M, Roggeri DP   +7 more
doaj  

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Frontiers in Pharmacology, 2022
Background: Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a
Luisa Ricciardi, Daniel Griscti Soler, Alessandra Bennici, Silvia Brunetto, Giovanni Pioggia, Sebastiano Gangemi   +5 more
doaj   +1 more source

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study

Frontiers in Immunology, 2023
IntroductionClinical remission as a multicomponent treatment goal in severe asthma is being explored in clinical practice. This post hoc analysis used data from the REDES study to assess the proportion of patients with severe eosinophilic asthma ...
Ian Pavord, Frances Gardiner, Liam G. Heaney, Christian Domingo, Robert G. Price, Alison Pullan, John Oppenheimer, Guy Brusselle, Hiroyuki Nagase, Geoffrey Chupp, Emilio Pizzichini, Emilio Pizzichini, David Bañas-Conejero, Peter Howarth   +13 more
doaj   +1 more source

Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications [PDF]

The Korean Journal of Internal Medicine, 2020
Asthma is commonly recognized as a heterogeneous condition with a complex pathophysiology. With advances in the development of multiple medications for patients with asthma, most asthma symptoms are well managed.
Youngwoo Choi, Soyoon Sim, Hae-Sim Park
doaj   +1 more source

Lactiplantibacillus Plantarum GUANKE Alleviates Allergic Asthma by Restricting Monocyte‐to‐DC Differentiation Via Microbiota‐Associated IAA

Advanced Science, EarlyView.
Lactiplantibacillus plantarum GUANKE remodels the indigenous gut microbiota and is associated with microbiota‐dependent restoration of circulating IAA. IAA treatment attenuates JAK3‐STAT3 and Jag1‐Notch4‐Hey1 signaling and reduces CX3CR1+Ly6C− monocytic precursor generation and pulmonary CD11b+ DC accumulation, together with reduced Th2 inflammation ...
Yujia He, Jielan Mi, Zhiping Zhao, Xiao Zhang, Zhihan Yang, Kun Yue, Yuanming Huang, Liqiong Song, Xiaoting Wen, Jianguo Xu, Zhihong Ren   +10 more
wiley   +1 more source

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice

, 2019
Background: Asthma is an inflammatory disease of the airways with symptoms that vary over time and intensity, sometimes leading to disability or even death. Eosinophilic asthma accounts for 25% of cases of severe asthma.
Olalla Montero-Pérez, Ernesto Sánchez-Gómez, María Beatriz Contreras-Rey   +2 more
core   +1 more source

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]

, 2013
Peer ...
Walsh, Garry Michael, Walsh GM
core   +1 more source

Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges

Advanced Science, EarlyView.
Nanomaterials offer dual applications in allergy management. For diagnosis, nanomaterials enhance analytical sensitivity and improve detection in specific IgE and functional assays such as the basophil activation test (BAT). For allergen‐specific immunotherapy, nanomaterials enable allergen masking and controlled release, and effectively modulate the ...
Madiha Habib, Shan Jiang, Joyce ZX Lee, CW Lim, HL Yeung, Nicki YH Leung, Patrick SC Leung, Ting F Leung, Christine YY Wai   +8 more
wiley   +1 more source